Singapore markets closed

Lyell Immunopharma, Inc. (LYEL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
6.52-0.19 (-2.83%)
As of 10:28AM EDT. Market open.
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2021
31/12/2020
31/12/2019
Total revenue
8,758
10,650
7,756
657
Operating expenses
Research development
132,994
138,693
182,243
63,595
Selling general and administrative
106,647
89,057
46,881
39,151
Total operating expenses
236,740
225,426
219,693
102,746
Operating income or loss
-227,982
-214,776
-211,937
-102,089
Total other income/expenses net
-36,546
-36,608
1,526
-35,409
Income before tax
-263,320
-250,219
-204,472
-129,377
Income from continuing operations
-263,320
-250,219
-204,472
-129,377
Net income
-263,320
-250,219
-204,472
-129,377
Net income available to common shareholders
-263,320
-250,219
-208,054
-130,521
Basic EPS
-
-1.84
-1.04
-0.62
Diluted EPS
-
-1.84
-1.04
-0.62
Basic average shares
-
135,918
200,327
211,746
Diluted average shares
-
135,918
200,327
211,746
EBITDA
-
-201,152
-207,643
-100,833